ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date
1. Introduction Lung cancer represents the leading cause of cancer deaths worldwide, with more than 1.8 million deaths in 2020 [1]; 85% are non-small-cell lung cancers (NSCLCs) and 25% of them harbor …
Selecting First-Line Therapy for ROS1 Fusion–Positive NSCLCs
4 ਜੂਨ 2025 · Question: What are the options for treating ROS1 fusion–positive NSCLCs, and what do you recommend as the first-line therapy? Answer: ROS1 fusions are found in up to 2% of NSCLCs. These …
Current Targeted Therapy Options in ROS1-Positive NSCLC - Pharmacy …
23 ਅਕਤੂ 2024 · ROS1 rearrangements in NSCLC are rare but significant, often leading to brain metastases and poor prognosis. ROS1-targeted therapies are preferred over immune checkpoint …
Advances and future directions in ROS1 fusion-positive lung cancer
23 ਅਗ 2024 · Understanding of the biology of ROS1 fusion-positive (ROS1+) non–small cell lung cancer (NSCLC) and treatment approaches has progressed immensely over the past decades, resulting in …
Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
10 ਜਨ 2024 · The early-generation ROS1 tyrosine kinase inhibitors (TKIs) that are approved for the treatment of ROS1 fusion–positive non–small-cell lung cancer (NSCLC) have antitumor activity, but ...
What do the new guidelines mean for ROS1-fusion positive and ALK ...
8 ਅਗ 2025 · An overview of guideline changes for ROS1-fusion positive & ALK-positive non-small cell lung cancer. Uncover how your treatment may change.
Array of Agents Allow for Treatment Individualization in ROS1+ NSCLC
27 ਜੁਲਾ 2025 · Jorge J. Nieva, MD, compares treatment options for patients with ROS1-positive non–small cell lung cancer.
JNCCN 360 - Non–Small Cell Lung Cancer - Repotrectinib for <em>ROS1…
6 ਦਸੰ 2024 · Efforts to improve the management of locally advanced and metastatic ROS1 fusion–positive non–small cell lung cancer (NSCLC) have resulted in significantly improved new …
Therapeutical Options in ROS1—Rearranged Advanced Non Small
15 ਜੁਲਾ 2023 · ROS proto-oncogene 1 (ROS1) rearrangements occur in 0.9–2.6% of patients with non small cell lung cancer (NSCLC), conferring sensitivity to treatment with specific tyrosine-kinase …
Repotrectinib Shrinks ROS1-Positive NSCLC Tumors - NCI
16 ਫ਼ਰ 2024 · Expanding treatment options for advanced lung cancers with ROS1 fusions ROS1 fusions occur when part of the gene breaks off and attaches to another gene. In lung cancer cells with the …
ਛੱਡ ਕੇ ਤਤਕਰੇ 'ਤੇ ਜਾਓ